Screener
ImmunityBio, Inc. IBRX Finite Lived Intangible Assets - Gross
Finite Lived Intangible Assets - Gross at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | March 31, 2026 / Weighted- Average Life Remaining(in years) | March 31, 2026 / Gross Carrying Amount | March 31, 2026 / Accumulated Amortization | Net Carrying Amount |
|---|---|---|---|---|
| Definite-lived: | ||||
| Favorable leasehold rights | 2.8 | $20,398 | $(8,946) | $11,452 |
| Developed technology | 4.3 | 542 | (81) | 461 |
| Total definite-lived assets | 20,940 | (9,027) | 11,913 | |
| Indefinite-lived: | ||||
| Goodwill | 910 | — | 910 | |
| In-process software development | 62 | — | 62 | |
| Total indefinite-lived assets | 972 | — | 972 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s finite lived intangible assets - gross?
- ImmunityBio, Inc. (IBRX) reported finite lived intangible assets - gross of $20.94M in Q1 2026.
- What does finite lived intangible assets - gross mean?
- This metric tracks the total historical cost of intangible assets that have a defined useful life, such as patents, software licenses, or customer relationships. It excludes assets with indefinite lives like certain trademarks or goodwill. It is a key indicator of the company's investment in intellectual property and intangible competitive advantages.
Ask your AI about ImmunityBio, Inc.'s finite lived intangible assets - gross.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude